The stars have aligned for Bristol Myers Squibb and Orbital Therapeutics. | The stars have aligned for Bristol Myers Squibb ...
ME Therapeutics has entered into a technology license agreement with the National Research Council of Canada to license a ...
Under the terms of the deal, Gilead will put down $120 million in an upfront payment and will promise up to $1.52 billion in ...
In vivo CD19 CAR T-cell therapy showed promising results in a feasibility study of five patients with refractory systemic ...
Researchers at the First Affiliated Hospital of the University of Science and Technology of China claim that an in vivo CD8 T ...
CD19-targeting UB-VV11 became the first in vivo CAR-T cell therapy to be cleared for human testing by the FDA last year, and ...
Poster presentation title: P53 mutant tumor regression across P53 mutations with AAN-53x, a P53 mRNA delivered with the PEP-NP tumor-targeted peptide (non-lipid) delivery system Presenter: Gilles ...
SHENZHEN, China, Sept. 17, 2025 /PRNewswire/ -- MagicRNA, a clinical-stage biotechnology company pioneering in vivo CAR T-cell therapies, today announced the publication of the world's first clinical ...
After axing a wide swath of federal research projects and grants, a recent slew of awards offers a glimpse into the kinds of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback